{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:24:28Z","timestamp":1793838268266,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970165"],"award-info":[{"award-number":["31970165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20379"],"award-info":[{"award-number":["U22A20379"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Plan of China"},{"name":"Special Foundation of the Chinese Academy of Sciences"},{"name":"Shanghai Science and Technology Committee in China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling COVID-19. Although Paxlovid and molnupiravir have received emergency approval from the FDA, some side effect concerns have emerged, and the possible oral agents are still limited, resulting in optimized drug development becoming an urgent requirement. An oral remdesivir derivative, VV116, has been reported to have promising antiviral effects against SARS-CoV-2 and positive therapeutic outcomes in clinical trials. However, whether VV116 has broad-spectrum anti-coronavirus activity and potential synergy with other drugs is not clear. Here, we uncovered the broad-spectrum antiviral potency of VV116 against SARS-CoV-2 variants of concern (VOCs), HCoV-OC43, and HCoV-229E in various cell lines. In vitro drug combination screening targeted RdRp and proteinase, highlighting the synergistic effect of VV116 and nirmatrelvir on HCoV-OC43 and SARS-CoV-2. When co-administrated with ritonavir, the combination of VV116 and nirmatrelvir showed significantly enhanced antiviral potency with noninteracting pharmacokinetic properties in mice. Our findings will facilitate clinical treatment with VV116 or VV116+nirmatrelvir combination to fight coronavirus infection.<\/jats:p>","DOI":"10.1038\/s41392-023-01587-1","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T20:01:52Z","timestamp":1695326512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1221","authenticated-orcid":false,"given":"Yumin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8244-7436","authenticated-orcid":false,"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-6315","authenticated-orcid":false,"given":"Hualiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-9934","authenticated-orcid":false,"given":"Jingshan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-235X","authenticated-orcid":false,"given":"Gengfu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-2571","authenticated-orcid":false,"given":"Leike","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"1587_CR1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490\u2013502 (2016).","journal-title":"Trends Microbiol."},{"key":"1587_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676\u2013679 (2005).","journal-title":"Science"},{"key":"1587_CR3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508\u20131513 (2015).","journal-title":"Nat. Med."},{"key":"1587_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of COVID-19\u2014final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1587_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner, C. D. et al. Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324, 1048\u20131057 (2020).","journal-title":"JAMA"},{"key":"1587_CR6","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569\u20131578 (2020).","journal-title":"Lancet"},{"key":"1587_CR7","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169, 104541 (2019).","journal-title":"Antiviral Res."},{"key":"1587_CR8","doi-asserted-by":"publisher","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1587_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41422-021-00570-1","volume":"31","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 31, 1212\u20131214 (2021).","journal-title":"Cell Res."},{"key":"1587_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2022","unstructured":"Cao, Z. et al. VV116 versus nirmatrelvir\u2013ritonavir for oral treatment of COVID-19. N. Engl. J. Med. 388, 406\u2013417 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1587_CR11","unstructured":"US Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir (US Food and Drug Administration, Silver Spring, MD, USA, 2022)."},{"key":"1587_CR12","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1093\/cid\/ciab1035","volume":"75","author":"BT Garibaldi","year":"2021","unstructured":"Garibaldi, B. T. et al. Real-world effectiveness of remdesivir in adults hospitalized with Covid-19: a retrospective, multicenter comparative effectiveness study. Clin. Infect. Dis. 75, e516\u2013e524 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1587_CR13","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1001\/jama.2022.9925","volume":"327","author":"R Rubin","year":"2022","unstructured":"Rubin, R. From positive to negative to positive again\u2014the mystery of why COVID-19 rebounds in some patients who take paxlovid. JAMA 327, 2380\u20132382 (2022).","journal-title":"JAMA"},{"key":"1587_CR14","unstructured":"Food and Drug Administration. FDA Updates on Paxlovid for Health Care Providers (US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD, 2022)."},{"key":"1587_CR15","doi-asserted-by":"publisher","first-page":"91ra63","DOI":"10.1126\/scitranslmed.3002304","volume":"3","author":"L Shen","year":"2011","unstructured":"Shen, L. et al. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci. Transl. Med. 3, 91ra63 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1587_CR16","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1093\/jac\/dkw203","volume":"71","author":"C Hawkins","year":"2016","unstructured":"Hawkins, C. et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV\/HCV-coinfected patients: a real-world perspective. J. Antimicrob. Chemother. 71, 2642\u20132645 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"1587_CR17","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/AAC.01509-08","volume":"53","author":"E Keyaerts","year":"2009","unstructured":"Keyaerts, E. et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob. Agents Chemother. 53, 3416\u20133421 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1587_CR18","doi-asserted-by":"publisher","first-page":"104646","DOI":"10.1016\/j.antiviral.2019.104646","volume":"173","author":"J Niu","year":"2020","unstructured":"Niu, J. et al. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. Antiviral Res. 173, 104646 (2020).","journal-title":"Antiviral Res."},{"key":"1587_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19891-7","volume":"11","author":"FS Oladunni","year":"2020","unstructured":"Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122 (2020).","journal-title":"Nat. Commun."},{"key":"1587_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41392-022-00963-7","volume":"7","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct. Target Ther. 7, 123 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1587_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1056\/NEJMc2214314","volume":"388","author":"J Miller","year":"2023","unstructured":"Miller, J. et al. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N. Engl. J. Med. 388, 662\u2013664 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1587_CR22","doi-asserted-by":"publisher","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","volume":"42","author":"P Qu","year":"2023","unstructured":"Qu, P. et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 42, 112443 (2023).","journal-title":"Cell Rep."},{"key":"1587_CR23","doi-asserted-by":"publisher","first-page":"e0022222","DOI":"10.1128\/aac.00222-22","volume":"66","author":"J Pitts","year":"2022","unstructured":"Pitts, J. et al. Remdesivir and GS-441524 retain antiviral activity against delta, omicron, and other emergent SARS-CoV-2 variants. Antimicrob. Agents Chemother. 66, e0022222 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1587_CR24","doi-asserted-by":"publisher","first-page":"105343","DOI":"10.1016\/j.antiviral.2022.105343","volume":"203","author":"T Weil","year":"2022","unstructured":"Weil, T., Lawrenz, J., Seidel, A., Munch, J. & Muller, J. A. Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor. Antiviral Res. 203, 105343 (2022).","journal-title":"Antiviral Res."},{"key":"1587_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"1587_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368, 1499\u20131504 (2020).","journal-title":"Science"},{"key":"1587_CR27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/22221751.2022.2078230","volume":"11","author":"Y Shen","year":"2022","unstructured":"Shen, Y. et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg. Microbes Infect. 11, 1518\u20131523 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"1587_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd2683","volume":"8","author":"J Jia","year":"2009","unstructured":"Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111\u2013128 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1587_CR29","doi-asserted-by":"publisher","first-page":"109133","DOI":"10.1016\/j.celrep.2021.109133","volume":"35","author":"K Bafna","year":"2021","unstructured":"Bafna, K. et al. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep. 35, 109133 (2021).","journal-title":"Cell Rep."},{"key":"1587_CR30","doi-asserted-by":"publisher","first-page":"105430","DOI":"10.1016\/j.antiviral.2022.105430","volume":"208","author":"JH Jeong","year":"2022","unstructured":"Jeong, J. H. et al. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. Antiviral Res. 208, 105430 (2022).","journal-title":"Antiviral Res."},{"key":"1587_CR31","doi-asserted-by":"publisher","first-page":"eabq7360","DOI":"10.1126\/scitranslmed.abq7360","volume":"15","author":"E Heilmann","year":"2023","unstructured":"Heilmann, E. et al. SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci. Transl. Med. 15, eabq7360 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1587_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"1587_CR33","doi-asserted-by":"publisher","first-page":"e0281522","DOI":"10.1128\/mbio.02815-22","volume":"14","author":"D Jochmans","year":"2023","unstructured":"Jochmans, D. et al. The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. mBio 14, e0281522 (2023).","journal-title":"mBio"},{"key":"1587_CR34","doi-asserted-by":"publisher","first-page":"e1009929","DOI":"10.1371\/journal.ppat.1009929","volume":"17","author":"AM Szemiel","year":"2021","unstructured":"Szemiel, A. M. et al. In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 17, e1009929 (2021).","journal-title":"PLoS Pathog."},{"key":"1587_CR35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.7883\/yoken.JJID.2015.292","volume":"68","author":"Y Matoba","year":"2015","unstructured":"Matoba, Y. et al. An outbreak of human coronavirus OC43 during the 2014-2015 influenza season in Yamagata, Japan. Jpn. J. Infect. Dis. 68, 442\u2013445 (2015).","journal-title":"Jpn. J. Infect. Dis."},{"key":"1587_CR36","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1073\/pnas.1610197114","volume":"114","author":"Y Koizumi","year":"2017","unstructured":"Koizumi, Y. et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc. Natl Acad. Sci. USA 114, 1922\u20131927 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1587_CR37","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493 (2020).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01587-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T13:02:19Z","timestamp":1700398939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01587-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"25 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.Z., Z.W., Y.X., Y.Z., G.X. and H.J. filed a patent application on pharmaceutical composition and its use.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}